NEW YORK (GenomeWeb) – Biocept reported after the close of the market on Wednesday that its second quarter revenues dropped 23 percent year over year.
For the three months ended June 30, the San Diego-based liquid biopsy firm had $917,471 in revenues compared to the $1.2 million it saw during the same quarter last year. These included $841,000 in commercial test revenue, $38,000 in development services test revenue, and $38,000 in revenue for distributed products, split between Biocept's Target Selector RUO kits and CEE-Sure blood collection tubes.